Pfizer Stock

Is Pfizer (PFE) Stock Worth To Buy After Announced An Additional 100 Million Doses Of COVID-19 Vaccine To EU?

Pfizer (NYSE: PFE) last Monday said that it with its partner BioNTech (Nasdaq: BNTX) will supply an additional 100 million doses of COVID-19 vaccine to the 27 EU member states this year. However, Pfizer's stock rose by only 1% after this news released, and then began to fall. The rising seems to be subject to some resistance. - April 27, 2021

Will Pfizer and BioNTech Become The Workhorse Of The EU's Vaccine Market?

Pfizer-BioNTech vaccine is marching towards the EU. - April 14, 2021

Pfizer to Develop mRNA Vaccines Without BioNTech | The Motley Fool

The pharmaceutical heavyweight thinks it won't need any more help to whip up new mRNA-based vaccines. - March 23, 2021

Why You Should Avoid Pfizer Stock Despite Its Covid-19 Vaccine

While Pfizer has a Covid-19 vaccine out for the public, PFE stock isn't getting much love from Wall Street. Let's avoid it for now. - March 23, 2021

Why Zoetis Is the Pfizer of Animal Healthcare | The Motley Fool

Zoetis has proven to investors that the pharmaceutical apple doesn't fall far from the tree. - March 16, 2021

Is Johnson & Johnson's COVID Vaccine Actually Better Than Pfizer's and Moderna's Vaccines? | The Motley Fool

Don't jump to any conclusions based on the different vaccines' advisory committee votes. - March 13, 2021

Pfizer Covid-19 Vaccine Updates: Will Demand Cool In 2022, Despite Growing Capacity?

Pfizer and its German partner BioNTech have indicated that they should have the capacity to produce as many as three billion doses of their Covid-19 vaccine in 2022, subject to demand. For perspective, Pfizer intends to produce about 2 billion doses of its shot this year and is projecting about... - March 11, 2021

Study: Pfizer and BioNTech Vaccine Neutralizes Brazil Coronavirus Variant | The Motley Fool

The two companies' BNT162b2 seems to protect patients against the fast-spreading variant. - March 09, 2021

Moderna and Pfizer's Second-Gen Coronavirus Vaccines: What Investors Need to Know | The Motley Fool

The competitive landscape is flattening out. - March 07, 2021

Why Pfizer Is Still a Top Stock for 2021 | The Motley Fool

Adding some of this pharma giant to your portfolio makes sense for the long run. - March 05, 2021

Where Will Pfizer Be in 1 Year? | The Motley Fool

The company will face competition on many fronts before 2022 arrives. - March 02, 2021

Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%? | The Motley Fool

Probably not in the way some might think. - March 02, 2021

3 Reasons to Buy Pfizer and 1 Reason to Sell | The Motley Fool

You'll probably be able to guess the top reason to buy this pharma stock. - February 28, 2021

Pfizer Has Gotten Better at Developing Drugs. Here's Why | The Motley Fool

The pharma giant is setting itself up for success, although a little luck also helps. - February 24, 2021

Pfizer Vaccine Updates: Possibly Easier Storage, Efficacy Against South African Strain

Last week, there were two positive developments relating to Pfizer and its German partner BioNTech’s Covid-19 vaccine, and one possible negative development. Firstly, Pfizer says based on internal testing that its vaccine can tolerate warmer temperatures than initially specified, possibly making... - February 23, 2021

Why Has Pfizer Stock Floundered? | The Motley Fool

There are two main reasons. At least one of them, though, isn't a problem anymore. - February 23, 2021

2 Reasons Pfizer's COVID Vaccine Prospects Just Got Even Better | The Motley Fool

The good news keeps on coming. - February 23, 2021

Warren Buffett Just Sold His Pfizer Stock. Should You? | The Motley Fool

You should definitely follow Buffett in one way. - February 21, 2021

Pfizer and BioNTech Coronavirus Vaccine Effective After 1 Dose, Can Last 2 Weeks in Standard Freezer, Separate Research Shows | The Motley Fool

The new findings promise simpler transport, storage, and administration for BNT162b2. - February 19, 2021

Pfizer and BioNTech Launch Coronavirus Vaccine Study for Pregnant Women | The Motley Fool

The testing will also be extended to children. - February 18, 2021

Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to EU

Pfizer (PFE)/BioNTech (BNTX) win a deal for 200 million more doses of its COVID-19 vaccine in Europe. - February 18, 2021

Pfizer: More Selling Likely? |

Stocks Analysis by JFD Team covering: Pfizer Inc. Read JFD Team's latest article on - February 16, 2021

Pfizer Could Be an Even Bigger Winner After These 2 Fantastic Findings | The Motley Fool

There's more good news for Pfizer's COVID-19 vaccine. - February 16, 2021

Pfizer (PFE) Gets FDA Nod for New Indication of Immunoglobulin

Pfizer's (PFE) Panzyga gets FDA approval to treat chronic inflammatory demyelinating polyneuropathy (CIDP), a rare neurological disease. - February 15, 2021

What's the Outlook for Pfizer Stock? | The Motley Fool

The pharmaceutical giant's future should be much brighter than its recent past. - February 14, 2021

Here's Why You Can't Compare Vaccine Results Between Johnson & Johnson, Pfizer, and Moderna | The Motley Fool

It's simply not an apples-to-apples comparison. - February 13, 2021

How Bad News for Xeljanz Could Affect Pfizer's Fortunes | The Motley Fool

The big drugmaker hoped for better news from a safety study of its blockbuster drug. - February 11, 2021

3 Reasons Pfizer's Failures Could Lead to a Big Acquisition | The Motley Fool

A huge pivot could reopen doors to growth that seemed closed. - February 11, 2021

What Are Pfizer's Prospects in 2021 and Beyond? | The Motley Fool

Hint: Better than the company's recent Q4 results might make you think. - February 10, 2021